Pelareorep + Chemotherapy + Bevacizumab (± Pelareorep)
Second-Line Colorectal Cancer (CRC)
Phase 1/2Planned - Biomarker-focused IST
Key Facts
Indication
Second-Line Colorectal Cancer (CRC)
Phase
Phase 1/2
Status
Planned - Biomarker-focused IST
Company
About Oncolytics Biotech
Oncolytics Biotech is advancing pelareorep, a unique oncolytic virus that selectively replicates in cancer cells and stimulates a systemic anti-tumor immune response. The company's strategy is centered on GI cancers, where it has generated compelling clinical data, including a 62% objective response rate in first-line mPDAC and more than doubled survival benchmarks in KRAS-mutant mCRC. With a seasoned leadership team and a clear focus on registration-enabling studies, Oncolytics aims to bring a novel, tolerable immunotherapy to patients facing devastating GI malignancies.
View full company profile